Ofatumumab
分子式：C6480H10022N1742O2020S44分子量：146.1KD
简介：Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation.
产品形式：蛋白原液。每种装于冻存管中，单抗质量为标示数量1MG或者5MG，体积根据其浓度不同略有不同。
质量标准：
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test：…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件：-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.
运输条件：干冰运输
使用建议：
meilunbio提供的产品为蛋白原液形式。每种装于冻存管中，单抗质量为标示数量1MG或者5MG，体积根据其浓度不同略有不同。
使用前可以根据自己实验需求进行稀释，溶剂建议用去离子无菌水(meilunbio货号MA0028，去离子无菌水(细胞培养用水))或者PBS（meilunbio货号MA0015PBS(1X),细胞培养级）。
不建议使用含有防腐成分的稀释液进行稀释，会增加细胞或者动物毒性。
稀释前，计算加入多少体积溶剂，请参考购买批次质检单上蛋白浓度，或者询问我司，
举例，质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
对应5MG包装的蛋白原液体积为5mg（质量）/50mg/ml(浓度)=0.1ML，
实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
若给药量为固定质量值，比如单次给药0.5MG，对应蛋白原液给药体积为10ul，建议稀释后，提高给药体积降低误差，因为注射器或者移液器吸头残留会影响实验效果。
稀释后的蛋白溶液，可于2-8度冷藏避光保存不超过2周，不建议长期储存。
避免反复冻融，每次冻融蛋白活性会降低约5%左右。
生物活性（仅来自于公开文献，不保证其有效性）
|
描述
|
Ofatumumab is a CD20-directed cytolytic monoclonal antibody with an inhibitory effect on early-stage B lymphocyte. It was approved by FDA for its use to treat patients with chronic lymphocytic leukemia (CLL) as an extended treatment or in combination with chlorambucil. It also has the thearapeutic effect on some other diseases such as follicular lymphoma. |
|
靶点 |
CD20 |
|
体内 |
Six- to 8-week-old SCID mice were inoculated subcutaneously on the posterior flank with 10 × 106 Z-138 cells suspended in Matrigel. Mice were monitored for establishment of a subcutaneous tumor nodule. Tumor volume was determined by caliper measurement as previously described (21). Once the tumor volume reached approximately 250 mm3, mice were assigned to either a control group, ofatumumab (10 mg/kg), or rituximab (10 mg/kg). Monoclonal antibodies were delivered IV via tail vein injection on days +0, +3, +7, and +10 following tumor engraftment. Tumor volume was monitored by serial caliper measurement. Mice with a tumor exceeding 2 cm in largest diameter were sacrificed as per RPCI IACUC requirements. Tumor size >2 cm in largest diameter was used as the survival endpoint in a Kaplan–Meier analysis. Differences in outcomes between treatment groups were compared by log-rank analysis. |
美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)
|
产品编号
|
品名. |
Target |
|
MB2806 |
aflibercept |
VEGFR |
|
MB2786 |
Alemtuzumab |
CD52 |
|
MB2787 |
Alirocumab |
PCSK9 |
|
MB2789 |
Avelumab |
PDL-1 |
|
MB2790 |
Atezolizumab |
PDL-1 |
|
MB2791 |
Bevacizumab |
VEGF |
|
MB2792 |
Cetuximab |
EGFR |
|
MB2803 |
Daratumumab |
CD38 |
|
MB2794 |
Denosumab |
RANK Ligand |
|
MB2023 |
Eculizumab |
补体蛋白(C5) |
|
MB2795 |
Etanercept |
TNF |
|
MB2797 |
Evolocumab |
PCSK9 |
|
MB2773 |
Infliximab |
TNF-α |
|
MB2769 |
Ipilimumab |
CTLA-4 |
|
MB2772 |
Matuzumab |
EGFR |
|
MB2766 |
Mepolizumab |
IL-5 |
|
MB2767 |
Nivolumab |
PD-1 |
|
MB2774 |
Obinutuzumab |
CD20 |
|
MB2784 |
Adalimumab |
TNF-α |
|
MB2777 |
Omalizumab |
IgE |
|
MB2781 |
Panitumumab |
EGFR |
|
MB2761 |
Pembrolizumab |
PD-1 |
|
MB2762 |
Pertuzumab |
HER2 |
|
MB2763 |
Ranibizumab |
VEGFR |
|
MB2938 |
Ramucirumab |
VEGFR |
|
MB2749 |
Rituximab |
CD20 |
|
MB2757 |
Secukinumab |
IL-17 |
|
MB2751 |
Tocilizumab/Atlizumab |
IL-6 receptor |
|
MB2753 |
Trastuzumab |
ErbB2 |
|
MB2758 |
Ustekinumab |
IL-12 |
用途及描述：仅供科研，严禁用于人体(For R&D Only)
我司所售出产品仅供于科研研究用途（非临床科研研究），每次销售产品行为都适用于我司网上所列明的通用销售条款。